



# The Feasibility Study of Non-Invasive Fetal Trisomy 18 and 21 Detection with Semiconductor Sequencing Platform

Young Joo Jeon<sup>1,2,9</sup>, Yulin Zhou<sup>3,9</sup>, Yihan Li<sup>4,9</sup>, Qiwei Guo<sup>3</sup>, Jinchun Chen<sup>4</sup>, Shengmao Quan<sup>5</sup>, Ahong Zhang<sup>5</sup>, Hailing Zheng<sup>5</sup>, Xingqiang Zhu<sup>5</sup>, Jin Lin<sup>5</sup>, Huan Xu<sup>5</sup>, Ayang Wu<sup>6</sup>, Sin-Gi Park<sup>1,2</sup>, Byung Chul Kim<sup>7,8</sup>, Hee Jae Joo<sup>1,2</sup>, Hongliang Chen<sup>5\*</sup>, Jong Bhak<sup>1,2,8,9\*</sup>

**1** TheragenEx Bio Institute, Suwon, Republic of Korea, **2** Genome Care, Seoul, South Korea, **3** Molecular Diagnostics Laboratory, Department of Medical Genetics, Prenatal Diagnosis Center, Xiamen Maternal and Child Health Hospital, Xiamen, Fujian, China, **4** Xiamen Hospital of Traditional Chinese Medicine, Fujian University of Traditional Chinese Medicine, Xiamen, Fujian, China, **5** Xiamen Vangenes BioTech, Xiamen, Fujian, China, **6** Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian, China, **7** Clinomics, Ulsan, Republic of Korea, **8** Personal Genomics Institute, Genome Research Foundation, Suwon, Republic of Korea, **9** BioMedical Engineering, UNIST, Ulsan, Republic of Korea

## Abstract

**Objective:** Recent non-invasive prenatal testing (NIPT) technologies are based on next-generation sequencing (NGS). NGS allows rapid and effective clinical diagnoses to be determined with two common sequencing systems: Illumina and Ion Torrent platforms. The majority of NIPT technology is associated with Illumina platform. We investigated whether fetal trisomy 18 and 21 were sensitively and specifically detectable by semiconductor sequencer: Ion Proton.

**Methods:** From March 2012 to October 2013, we enrolled 155 pregnant women with fetuses who were diagnosed as high risk of fetal defects at Xiamen Maternal & Child Health Care Hospital (Xiamen, Fujian, China). Adapter-ligated DNA libraries were analyzed by the Ion Proton™ System (Life Technologies, Grand Island, NY, USA) with an average 0.3× sequencing coverage per nucleotide. Average total raw reads per sample was 6.5 million and mean rate of uniquely mapped reads was 59.0%. The results of this study were derived from BWA mapping. Z-score was used for fetal trisomy 18 and 21 detection.

**Results:** Interactive dot diagrams showed the minimal z-score values to discriminate negative versus positive cases of fetal trisomy 18 and 21. For fetal trisomy 18, the minimal z-score value of 2.459 showed 100% positive predictive and negative predictive values. The minimal z-score of 2.566 was used to classify negative versus positive cases of fetal trisomy 21.

**Conclusion:** These results provide the evidence that fetal trisomy 18 and 21 detection can be performed with semiconductor sequencer. Our data also suggest that a prospective study should be performed with a larger cohort of clinically diverse obstetrics patients.

**Citation:** Jeon YJ, Zhou Y, Li Y, Guo Q, Chen J, et al. (2014) The Feasibility Study of Non-Invasive Fetal Trisomy 18 and 21 Detection with Semiconductor Sequencing Platform. *PLoS ONE* 9(10): e110240. doi:10.1371/journal.pone.0110240

**Editor:** Sinuhe Hahn, University Hospital Basel, Switzerland

**Received:** June 11, 2014; **Accepted:** September 11, 2014; **Published:** October 20, 2014

**Copyright:** © 2014 Jeon et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability:** The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper. Sequence data has been deposited in the NIH short read archive (SRA) with the following BioProject accession number: SRP044689

**Funding:** This work was supported by the Industrial Strategic Technology Development Program, 10040231, 'Bioinformatics platform development for next generation bioinformation analysis' funded by the Ministry of Knowledge Economy (MKE, Korea). Co-authors Young Joo Jeon, Sin-Gi Park, Hee Jae Joo, and Jong Bhak are employed by TheragenEx Bio Institute. TheragenEx Bio Institute provided support in the form of salaries for authors YJJ, SGP, HJJ, and JB, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. Co-authors Young Joo Jeon, Sin-Gi Park, Hee Jae Joo, and Jong Bhak are employed by Genome Care. Genome Care provided support in the form of salaries for authors YJJ, SGP, HJJ, and JB, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. Co-authors Shengmao Quan, Ahong Zhang, Hailing Zheng, Xingqiang Zhu, Jin Lin, Huan Xu, and Hongliang Chen are employed by Xiamen Vangenes BioTech. Xiamen Vangenes BioTech provided support in the form of salaries for authors SQ, AZ, HZ, XZ, JL, HX, and HC, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. Co-author Byung Chul Kim is employed by Clinomics. Clinomics provided support in the form of salaries for author BCK, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of this author are articulated in the 'author contributions' section.

**Competing Interests:** We have the following interests: co-authors Young Joo Jeon, Sin-Gi Park, Hee Jae Joo, and Jong Bhak are employed by TheragenEx Bio Institute. Co-authors Young Joo Jeon, Sin-Gi Park, Hee Jae Joo, and Jong Bhak are employed by Genome Care. Co-authors Shengmao Quan, Ahong Zhang, Hailing Zheng, Xingqiang Zhu, Jin Lin, Huan Xu, and Hongliang Chen are employed by Xiamen Vangenes BioTech. Co-author Byung Chul Kim is employed by Clinomics. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.

\* Email: hongliangchen@gmail.com (HC); jongbhak@genomics.org (JB)

† These authors contributed equally to this work.

## Introduction

Prenatal screening and diagnostics for fetal chromosomal aneuploidy are well established worldwide for pregnant women [1,2]. Predictive testing during the first trimester includes a combination of fetal ultrasound and maternal serum biomarkers [3]. Women with fetuses at high risk of defects are also provided opportunities for invasive diagnostic testing, such as chorionic villus sampling (CVS) at 12 weeks of gestation and amniocentesis at 15 weeks of gestation [4,5]. Although these invasive tests are highly accurate, they are associated with iatrogenic pregnancy loss [6].

The prevalence rate of the common aneuploidy, trisomy 21, is around 1 in 500 in the group of women that request screening. In contrast, 1 in 200 women who receive first-trimester screening (FTS) are categorized as increased risk. The main reason that many women avoid testing or screening is because they are aware of the risks associated with invasive testing [7]. Further, FTS has two serious limitations; FTS has a false-negative rate of 10–25% and a restricted time-window of 11–13 gestational weeks [8–12].

After Lo et al. discovered fetal cell-free DNA (cfDNA) floating in maternal blood [13], there have been concerted attempts to perform non-invasive prenatal testing (NIPT) with cfDNA [14]. The cfDNA is originated from apoptotic trophoblasts in the placenta [13]. On average, the amount of cfDNA in plasma from a pregnant woman is approximately 10% during 10–22 weeks of gestation but there is a large variance in the fraction of cfDNA between individuals [15]. The typical cfDNA size is approximately 150 base pairs (bp) [16]. The half-life of cfDNA is very short [17], and fetal DNA fragments of maternal blood are no longer detectable after birth [18]. Despite these limitations, NIPT consists of well-accepted and advanced technologies. NIPT has two key clinical advantages compared with those of invasive prenatal testing; it does not confer a risk of pregnancy loss, and can be performed during early pregnancy. However, NIPT is not currently considered to be fully diagnostic and requires invasive testing to confirm positive results because the discordant NIPT data for detecting chromosomal abnormality have resulted from placental or maternal cell mosaicism [19–21]. To minimize this problem, risk scores and multiple cut-offs have been often used for NIPT services [14].

Recent NIPT technologies are based on next-generation sequencing (NGS) [22–27]. NGS allows rapid and effective clinical diagnostic testing with two commonly used systems, the Illumina and Ion Torrent platforms. Ion Torrent, semiconductor sequencing platform, enables acquisition of sequencing data within 2 to 4 hours, thus the sequencer may provide an alternative clinical sequencing service with a reduced turn-around time. The majority of NIPT technology is associated with Illumina platform. Previous NIPT studies with the Illumina platform report consistent data for common aneuploidies, particularly trisomy 18 and 21; sensitivity and specificity are each higher than 98% [22–26]. A recent study reports the results for non-invasive detection of common fetal trisomy 13, 18, and 21 with Ion Proton, a semiconductor sequencer [27]. The sensitivity and specificity of the common fetal aneuploidies (Trisomy 13, 18, and 21) are each higher than 98% [27]. However, more references of non-invasive fetal aneuploidy detection with semiconductor sequencing platform are required.

In our study, we performed NIPT for fetal trisomy 18 and 21 with Ion Proton. The testing results of semiconductor sequencing platform have rarely been reported as an NIPT technology [27]. Therefore, we investigated whether fetal trisomy 18 and 21 were sensitively and specifically detectable by Ion Proton.

## Materials and Methods

### Study Subjects

From March 2012 to October 2013, we enrolled 155 pregnant women with fetuses who were diagnosed as high risk of fetal defects at Xiamen Maternal & Child Health Care Hospital (Xiamen, Fujian, China). 28 pregnant women (18.1%) were 12–16 weeks of gestation, 86 women (55.5%) were 17–21 weeks of gestation, and 41 women with fetuses (26.5%) were more than 22 weeks of gestation. Pregnant women who were scheduled to receive invasive diagnostic testing (Amniocentesis) for fetal karyotyping were asked to donate a blood sample before having the invasive test. Women who gave written informed consent participated in the study if they were  $\geq 19$  years old and had a singleton pregnancy with a gestational age of at least 12 weeks. The institutional review board at Xiamen Maternal & Child Health Care Hospital approved this study.

We used the results of standard prenatal aneuploidy screening with individual risk scores and interpretations produced by accredited clinical laboratories for sorting out high risk group of fetal defects. First-trimester serum markers included pregnancy-associated plasma protein A (PAPP-A) and free beta subunit or total human chorionic gonadotropin (hCG). Second-trimester serum markers included maternal serum alpha-fetoprotein (MSAFP), hCG, unconjugated estriol, and inhibin A. First-trimester serum markers were used in combination with sonographic measurement of fetal nuchal translucency (combined FTS test) to categorize patients into high or low risk groups. Second-trimester serum values were evaluated alone (quadruple screening test) or in combination with FTS results to define aneuploidy risk. To determine fetal karyotypes, fetal cells from amniotic fluid were cultured to test for chromosomal abnormalities by the method of Barch et al [28]. Cytogenetic analysis performed on all 155 fetal cells indicated that 139 (89.7%) were chromosomally normal, 5 (3.2%) were trisomy 18, and 11 (7.1%) were trisomy 21.

### Cell-free DNA Preparation and Sequencing

Eligible subjects were asked to participate in the study after receiving counseling about the invasive diagnostic test. Approximately 10 mL of whole blood was collected from each subject and placed in a Cell-Free DNA BCT™ tube (Streck, Omaha, NE, USA) before the invasive procedure. Within 6 hours of collection, the maternal blood samples were centrifuged first at 1,200 $\times$ g for 15 min at 4°C. Plasma was transferred to microcentrifuge tubes, centrifuged again at 16,000 $\times$ g for 10 min at 4°C to remove residual cells, transferred to fresh tubes, and stored at  $-80^{\circ}\text{C}$ . For each sample, plasma cfDNA was extracted from 1 mL of plasma using the QIAamp Circulating Nucleic Acid Kit from Qiagen (Hilden, Germany). The resulting plasma cfDNA was used as input DNA to make a library for sequencing. End-repair of the plasma cfDNA was performed with T4 DNA polymerase, Klenow DNA polymerase, and T4 polynucleotide kinase. The adapter-ligated DNA libraries were analyzed with the Ion Proton™ System (Life Technologies, Grand Island, NY, USA) with an average 0.3 $\times$ sequencing coverage per nucleotide. Ion PI™ Chip Kit version 2.0 (Life Technologies) was used for cfDNA sequencing and 10 cfDNA samples per chip were analyzed. Average total raw reads per sample was 6.5 million and mean rate of uniquely mapped reads was 59.0%.

### Data Analysis

Raw reads with different lengths acquired from the Ion Torrent Suite software trimmed from the 3' end by sequencing quality

**Table 1.** Demographic characteristics of study subjects.

Demographic characteristics	Euploid (n = 139)	T18 (n = 5)	T21 (n = 11)	Total (n = 155)
Maternal age, years, mean±SD	30.61±5.01	27.60±5.50	33.64±3.29	30.73±4.99
≥ 35 years (%)	36 (25.9)	1 (20.0)	5 (45.5)	42 (27.1)
NIPT during 12–16 gestational weeks (%)	25 (18.0)	1 (20.0)	2 (18.2)	28 (18.1)
NIPT during 17–21 gestational weeks (%)	78 (56.1)	4 (80.0)	4 (36.4)	86 (55.5)
NIPT ≥ 22 gestational weeks (%)	36 (25.9)	0 (0.0)	5 (45.5)	41 (26.5)
Male fetus (%)	65 (46.8)	4 (80.0)	9 (81.8)	78 (50.3)
Female fetus (%)	74 (53.2)	1 (20.0)	2 (18.2)	77 (49.7)
Z-score of chr18 (min, max)	-3.184, 2.459	4.017, 10.193	-1.730, 1.592	-3.184, 10.193
Z-score of chr21 (min, max)	-3.080, 2.566	-1.449, 0.387	4.693, 30.943	-3.080, 30.943

T18, Trisomy 18; T21, Trisomy 21; SD, standard deviation; NIPT, non-invasive prenatal testing.  
doi:10.1371/journal.pone.0110240.t001

value of >15, and filtered by read length (<50 bp) and GC contents (35%–45%). Duplicate reads were identified by Picard (<http://picard.sourceforge.net/>) with the default parameters and removed by in-house python script. The sequences were binned for each sample according to the index and mapped to the unmasked human genome sequence (hg19). We tested several mapping software programs, including BWA [29], Bowtie [30], and SOAP2 [31]. The results in this study were derived from the BWA mapping analysis. All chromosomes were divided into segments with a bin size of 300 kb to calculate z-score for fetal trisomy 18 and 21 detection. For the 155 samples, we calculated the z-score for each chromosome of each sample to examine fetal aneuploidy with mapped reads for each sample, and mean mapped reads and standard deviation (SD) of 139 euploid samples. For example, the z-score of case 1 for chr21 could be calculated as follows:  $z\text{-score}_{chr21\_case1} = (\text{mapped reads of } chr21_{case1} - \text{mean mapped reads of } chr21_{euploid\ group}) / (\text{SD for mean mapped reads of } chr21_{euploid\ group})$ . The minimal z-scores to classify negative versus positive cases of trisomy based on interactive dot diagrams were > 2.459 for fetal trisomy 18 and >2.566 for fetal trisomy 21. Sequence data has been deposited in the NIH short read archive (SRA) with the following BioProject accession number: SRP044689.


**Statistical Analysis**

Categorical variables were summarized with the number and percentage of subjects. Continuous variables were described as means with SD. Positive predictive value (PPV) and negative predictive value (NPV) were calculated with standard formulas for binomial distributions. Wilson’s interval method was used to calculate 95% confidence intervals (CI). Interactive dot diagrams were used to assign classifications according to the presence of fetal aneuploidy. Analyses were performed with MedCalc version 12.1.4 (MedCalc Software bvba, Ostend, Belgium).

**Results**

Table 1 shows the demographic characteristics of the enrolled participants in this study. The mean maternal age of this study cohort was 30.73±4.99 years (range 19–43 years). 28 pregnant women (18.1%) received NIPT during 12–16 weeks of gestation, 86 women (55.5%) received testing during 17–21 weeks of gestation, and 41 women with fetuses (26.5%) who were more than 22 weeks of gestation received testing. The ratio of male (50.3%) to female (49.7%) fetuses was nearly 1:1; however, in aneuploidies, the ratio of male (81.3%) to female fetuses (13.8%) was 13:3.

Figure 1 presents interactive dot diagrams for fetal trisomy 18 and 21 showed the minimal z-score values of 100% PPV and NPV. For fetal trisomy 18, the minimal z-score value of 2.459



**Figure 1. Interactive dot diagrams of trisomy 18 and 21.** (A) Interactive dot diagram of trisomy 18. (B) Interactive dot diagram of trisomy 21.  
doi:10.1371/journal.pone.0110240.g001

**Table 2.** Positive predictive and negative predictive values in this study.

Aneuploidy	Positive predictive value (95% CI)	Negative predictive value (95% CI)
T18 (n = 5)	100.0% (47.8%–100.0%)	100.0% (97.6%–100.0%)
T21 (n = 11)	100.0% (71.5%–100.0%)	100.0% (97.5%–100.0%)
Combined detection (n = 16)	100.0% (79.4%–100.0%)	100.0% (97.4%–100.0%)

T18, trisomy 18; T21, trisomy 21.  
doi:10.1371/journal.pone.0110240.t002

showed 100% PPV and NPV. The minimal z-score of 2.566 was used to classify negative versus positive cases of fetal trisomy 21.

Table 2 summarizes the PPVs and NPVs of the NIPT results for fetal trisomy 18 and 21. For fetal trisomy 18, the PPV (95% CI: 47.8%–100.0%) and NPV (95% CI: 97.6%–100.0%) were 100%. The PPV (95% CI: 71.5%–100.0%) and NPV (95% CI: 97.5%–100.0%) for detecting fetal trisomy 21 were also 100%. On the whole, the PPV (95% CI: 79.4%–100.0%) and NPV (95% CI: 97.4%–100.0%) of combined detection of fetal trisomy 18 and 21 were 100%.

## Discussion

We have examined the feasibility of NIPT using cfDNA in a predominantly high-risk obstetrics population using the semiconductor sequencing system: Ion Proton. Fetal trisomy 18 and 21 were non-invasively detectable with 100% PPV and NPV. The results of present study provide the evidence that non-invasive fetal trisomy 18 and 21 detection can be performed with semiconductor sequencing platform. However, our test is still far away from a clinically validated test because there was not consideration for plasma fetal DNA fraction.

According to previous reports, the Ion Torrent sequencer shows equivalent performance to the Illumina platform [32–34]. Quail et al. [32] measured Ion Torrent PGM data against Illumina HiSeq2000 and MiSeq results, and found that the error rate of Ion Torrent PGM data was 1.78%. In contrast, Illumina HiSeq2000 and MiSeq platforms demonstrated error rates ranging from 0.26% to 0.80%, and the rates of true single nucleotide polymorphisms (SNPs) were higher for Ion Torrent PGM analysis compared to that of the Illumina HiSeq2000 and MiSeq analysis [32]. Boland et al. [33] demonstrated that Ion Proton genotyping data were nearly concordant with SNP microarray data; further, the concordance rates were similar to those of the Illumina HiSeq2000 results. Chen et al. [34] compared the performances of the Ion Proton and Illumina MiSeq systems for ultra-low coverage sequencing. Ion Proton and Illumina MiSeq platforms present similar coverage for relative depth (RD) at each 1-Mbp of sequencing for GC-content. Both sequencing systems correctly detected fetal tissue aneuploidies [34]. Ion Proton system can construct ~80 million raw reads in 3–4 hours, which allows chromosomal abnormality detection within 1–2 working days, is advantageous for applications that require precise turn-around times, such as prenatal genetic screening [34].

Conventional noninvasive aneuploidy screening tests are not straight forward. None of the screening tests are ideal, because detection rates for chromosomal abnormalities are less than 100%. By definition, the false-positive rate is 5% if modeled for a common obstetrics population. Maternal serum marker and ultrasound screening tests have been performed widely for over a decade. These have been popular but have limitations. Henry et

al. [35] analyzed the birth of Down's syndrome after routine noninvasive screening largely replaced age-related invasive procedures in Colorado from 1989 to 2005. Despite the increase in prenatal screening, neonates with trisomy 21 increased in women over 35 years of age. One explanation is that women did not receive the recommended protocol, perhaps incorrectly assuming that a single blood test would definitively detect abnormalities.

Serum biomarker analysis and ultrasound sonography do not definitively detect chromosomal aneuploidy. A positive screen result must be followed up with an invasive prenatal test (CVS or amniocentesis) to determine whether fetal aneuploidy is truly present. Previous studies of NIPT with cfDNA report consistently accurate results for detecting common aneuploidies, particular trisomy 18 and 21 [22–27]. However, the cost of the test is a major issue. Currently, the cost of a plasma cfDNA test ranges from about \$800 to \$2,000 in the US and from \$500 to \$1,500 in other countries [14]. Two previously published reports have estimated costs when the cfDNA test is applied to women with positive conventional screening results [36,37]. They concluded that applying the cfDNA test was connected to a net cost reduction in comparison with CVS or amniocentesis [36,37].

In summary, we investigated whether fetal trisomy 18 and 21 could be detected by noninvasive Ion Torrent sequencing as has previously been published for Illumina sequencing. However, the present study has several limitations. First, our sample size was smaller than other obstetrics populations in previous reports [22–27]. The lower 95% CIs for NPV were almost 97.0% in our study, whereas other studies usually demonstrate >98.0% of the lower 95% CIs for specificity. More than 400 high-risk pregnant women will need to be enrolled in future studies to estimate >98.0% of the lower 95% CIs for NPV or specificity with Wilson's interval method. Second, we did not find any positive cases for rare chromosomal abnormalities, such as trisomy 9, trisomy 13, and sex chromosome aneuploidies. Third, the participation rates for low-risk pregnant women after serum biomarker testing and ultrasound sonography did not reach expected levels. Fourth, we could not measure Ion Proton sequencing data against data that were analyzed by Illumina HiSeq or MiSeq due to insufficient quantities of blood samples. Although the results of our study provide initial evidence for NIPT of fetal trisomy 18 and 21 using the semiconductor sequencing system, a prospective study on a larger cohort of clinically diverse obstetrics participants is warranted to validate these findings.

## Author Contributions

Conceived and designed the experiments: YJJ YZ YL HC JB. Performed the experiments: SQ AZ HZ XZ JL HX. Analyzed the data: YJJ SGP JB. Contributed reagents/materials/analysis tools: YZ YL QG JC AW BCK HJJ HC. Contributed to the writing of the manuscript: YJJ YZ YL HC JB.

## References

- Morgan S, Delbarre A, Ward P (2013) Impact of introducing a national policy for prenatal Down syndrome screening on the diagnostic invasive procedure rate in England. *Ultrasound Obstet Gynecol* 41: 526–529.
- ACOG Committee on Practice Bulletins (2007) ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. *Obstet Gynecol* 109: 217–227.
- Nicolaides KH (2011) Screening for fetal aneuploidies at 11 to 13 weeks. *Prenat Diagn* 31: 7–15.
- Fortuny A, Borrell A, Soler A, Casals E, Costa D, et al. (1995) Chorionic villus sampling by biopsy forceps. Results of 1580 procedures from a single centre. *Prenat Diagn* 15: 541–550.
- Crandall BF, Kulch P, Tabsh K (1994) Risk assessment of amniocentesis between 11 and 15 weeks: comparison to later amniocentesis controls. *Prenat Diagn* 14: 913–919.
- Tabor A, Alfirevic Z (2010) Update on procedure-related risks for prenatal diagnosis techniques. *Fetal Diagn Ther* 27: 1–7.
- van den Berg M, Timmermans DR, Kleinveld JH, Garcia E, van Vugt JM, et al. (2005) Accepting or declining the offer of prenatal screening for congenital defects: test uptake and women's reasons. *Prenat Diagn* 25: 84–90.
- Borrell A, Casals E, Fortuny A, Farre MT, Gonce A, et al. (2004) First-trimester screening for trisomy 21 combining biochemistry and ultrasound at individually optimal gestational ages. An interventional study. *Prenat Diagn* 24: 541–545.
- Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH (2008) Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. *Ultrasound Obstet Gynecol* 31: 618–624.
- Berkold L, von Kaisenberg CS, Hillemanns P, Vaske B, Schmidt P (2013) Analysis of the impact of PAPP-A, free  $\beta$ -hCG and nuchal translucency thickness on the advanced first trimester screening. *Arch Gynecol Obstet* 287: 413–420.
- Muñoz-Cortes M, Arigita M, Falguera G, Seres A, Guix D, et al. (2012) Contingent screening for Down syndrome completed in the first trimester: a multicenter study. *Ultrasound Obstet Gynecol* 39: 396–400.
- Sainz JA, Serrano R, Borrero C, Turmo E (2012) First trimester contingent test as a screening method for Down's syndrome. A prospective study in the general population. *J Matern Fetal Neonatal Med* 25: 2221–2224.
- Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, et al. (1997) Presence of fetal DNA in maternal plasma and serum. *Lancet* 350: 485–487.
- Benn P, Cuckle H, Pergament E (2013) Non-invasive prenatal testing for aneuploidy: current status and future prospects. *Ultrasound Obstet Gynecol* 42: 15–33.
- Norton ME, Brar H, Weiss J, Karimi A, Laurent LC, et al. (2012) Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. *Am J Obstet Gynecol* 207: 137.e1–8.
- Chan KC, Zhang J, Hui AB, Wong N, Lau TK, et al. (2004) Size distributions of maternal and fetal DNA in maternal plasma. *Clin Chem* 50: 88–92.
- Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, et al. (1999) Rapid clearance of fetal DNA from maternal plasma. *Am J Hum Genet* 64: 218–224.
- Smid M, Galbiati S, Vassallo A, Gambini D, Ferrari A, et al. (2003) No evidence of fetal DNA persistence in maternal plasma after pregnancy. *Hum Genet* 112: 617–618.
- Grati FR, Malvestiti F, Ferreira JC, Bajaj K, Gaetani E, et al. (in press) Fetoplacental mosaicism: potential implications for false-positive and false-negative noninvasive prenatal screening results. *Genet Med* DOI: 10.1038/gim.2014.3.
- McNamara CJ, Limone LA, Westover T, Miller RC (2014) Maternal source of false-positive fetal sex chromosome aneuploidy in noninvasive prenatal testing. *Obstet Gynecol* 123: 69S–70S.
- Wang Y, Chen Y, Tian F, Zhang J, Song Z, et al. (2014) Maternal mosaicism is a significant contributor to discordant sex chromosomal aneuploidies associated with noninvasive prenatal testing. *Clin Chem* 60: 251–259.
- Bianchi DW, Parker RL, Wentworth J, Madankumar R, Saffer C, et al. (2014) DNA sequencing versus standard prenatal aneuploidy screening. *N Engl J Med* 370: 799–808.
- Sparks AB, Struble CA, Wang ET, Song K, Oliphant A (2012) Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. *Am J Obstet Gynecol* 206: 319.e1–9.
- Lau TK, Cheung SW, Lo PS, Pursley AN, Chan MK, et al. (2014) Non-invasive prenatal testing for fetal chromosomal abnormalities by low-coverage whole-genome sequencing of maternal plasma DNA: review of 1982 consecutive cases in a single center. *Ultrasound Obstet Gynecol* 43: 254–264.
- Ehrlich M, Deciu C, Zwiefelhofer T, Tynan JA, Cagasan L, et al. (2011) Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. *Am J Obstet Gynecol* 204: 205.e1–11.
- Ashoor G, Syngelaki A, Wagner M, Birdir C, Nicolaides KH (2012) Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. *Am J Obstet Gynecol* 206: 322.e1–5.
- Liao C, Yin AH, Peng CF, Fu F, Yang JX, et al. (2014) Noninvasive prenatal diagnosis of common aneuploidies by semiconductor sequencing. *Proc Natl Acad Sci U S A* 111: 7415–7420.
- Barch MJ, Knutsen T, Spurbeck JL (1997) The AGT Cytogenetics Laboratory Manual, 3rd edn. New York: Lippincott-Raven publishers.
- Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 25: 1754–1760.
- Langmead B, Trapnell C, Pop M, Salzberg SL (2009) Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol* 10: R25.
- Li R, Yu C, Li Y, Lam TW, Yiu SM, et al. (2009) SOAP2: an improved ultrafast tool for short read alignment. *Bioinformatics* 25: 1966–1967.
- Quail MA, Smith M, Coupland P, Otto TD, Harris SR, et al. (2012) A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. *BMC Genomics* 13: 341.
- Boland JF, Chung CC, Roberson D, Mitchell J, Zhang X, et al. (2013) The new sequencer on the block: comparison of Life Technology's Proton sequencer to an Illumina HiSeq for whole-exome sequencing. *Hum Genet* 132: 1153–1163.
- Chen S, Li S, Xie W, Li X, Zhang C, et al. (2014) Performance Comparison between Rapid Sequencing Platforms for Ultra-Low Coverage Sequencing Strategy. *PLoS One* 9: e92192.
- Henry GP, Britt DW, Evans MI (2008) Screening advances and diagnostic choice: the problem of residual risk. *Fetal Diagn Ther* 23: 308–315.
- Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, et al. (2011) DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. *Genet Med* 13: 913–920.
- Song K, Musci TJ, Caughey AB (2013) Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population. *J Matern Fetal Neonatal Med* 26: 1180–1185.